tuberculosis

From manipulating host molecules to concealing their presence in the host’s body, microbes employ a wide range of tactics to dodge immune detection.

Two autophagy genes work together to stop Mycobacterium tuberculosis dead in its tracks.

The results could help guide the design of new vaccines for the disease.

The genome is from a male who was likely in his late thirties when the historic Mount Vesuvius eruption occurred. The analyses suggest he is related to the diverse Imperial Roman population of the time, and that he may have suffered from spinal tuberculosis.

Overbearing restrictions on research into toxins and pathogens such as SARS-CoV-2 could undermine public health and security in the long run.

More than a dozen vaccines for tuberculosis are currently being tested in clinical trials. Some use whole bacteria as BCG does, while others deliver protein subunits or genetic material carried by viral vectors.  

This month marks the 100-year anniversary of BCG, still the only approved vaccine against the lethal pathogen. But there are new vaccines for this wily foe on the horizon.

One hundred years after its invention, BCG has stood the test of time as a vaccine against tuberculosis.

Some researchers have turned their focus to artificial intelligence to study an underused symptom common to most respiratory pathogens—cough.

A recent study elucidates some of the changes that occur in the body after inoculation with a tuberculosis vaccine.

As researchers test existing vaccines for nonspecific protection against COVID-19, immunologists are working to understand how some inoculations protect against pathogens they weren’t designed to fend off.

Studies are underway to test whether giving a shot of BCG vaccine could protect doctors and nurses against COVID-19.

Researchers used a machine-learning platform to test more than 100 million molecules for antibacterial activity.

Tested in patients with the latent form of tuberculosis, the vaccine prevented the development of the active form of infection in 50 percent more individuals compared with unvaccinated patients.

An early-stage, blood-based assay shows potential as a method for sorting patients with suspected TB from those with other respiratory illnesses.

The US Food and Drug Administration green lights a therapy for an extreme form of multidrug resistant TB.

Tweaking the genomes of two phages and combining them with a third phage helped to clear a persistent Mycobacterium infection in the patient.

At least a handful of patients have developed active TB after receiving cancer treatment designed to boost the immune system’s antitumor response.